NeurAxis Stock Doubles with FDA Clearance for IB-Stim

Dow Jones

May 20, 2025

By Dean Seal

Shares of NeurAxis more than doubled after regulators cleared its IB-Stim treatment for pediatric functional abdominal pain related to functional dyspepsia.

The stock briefly touched a record high of $6.20 before settling back around $4.97 in early trading. Shares closed the market at $5.27 this time a year ago.

The medical technology company said before the opening bell that the U.S. Food and Drug Administration's 510(k) clearance for IB-Stim in patients aged 8 to 21 marks the first time that the FDA has approved a treatment related to functional dyspepsia.

This is also the second successful expansion of the FDA's indication for IB-Stim after previously getting it approved for abdominal pain associated with irritable bowel syndrome, NeurAxis said.

Write to Dean Seal at dean.seal@wsj.com

(END) Dow Jones Newswires

May 20, 2025 10:20 ET (14:20 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2536645735"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2536645735\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2536645735?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-20 22:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2536645735","market":"fut","top_or_hot":-1,"title":"NeurAxis Stock Doubles with FDA Clearance for IB-Stim","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Dean Seal \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of NeurAxis more than doubled after regulators cleared its IB-Stim treatment for pediatric functional abdominal pain related to functional dyspepsia. \n</p>\n<p>\n  The stock briefly touched a record high of $6.20 before settling back around $4.97 in early trading. Shares closed the market at $5.27 this time a year ago. \n</p>\n<p>\n  The medical technology company said before the opening bell that the U.S. Food and Drug Administration's 510(k) clearance for IB-Stim in patients aged 8 to 21 marks the first time that the FDA has approved a treatment related to functional dyspepsia. \n</p>\n<p>\n  This is also the second successful expansion of the FDA's indication for IB-Stim after previously getting it approved for abdominal pain associated with irritable bowel syndrome, NeurAxis said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 20, 2025 10:20 ET (14:20 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NeurAxis Stock Doubles with FDA Clearance for IB-Stim</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeurAxis Stock Doubles with FDA Clearance for IB-Stim\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-05-20 22:20</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Dean Seal \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of NeurAxis more than doubled after regulators cleared its IB-Stim treatment for pediatric functional abdominal pain related to functional dyspepsia. \n</p>\n<p>\n  The stock briefly touched a record high of $6.20 before settling back around $4.97 in early trading. Shares closed the market at $5.27 this time a year ago. \n</p>\n<p>\n  The medical technology company said before the opening bell that the U.S. Food and Drug Administration's 510(k) clearance for IB-Stim in patients aged 8 to 21 marks the first time that the FDA has approved a treatment related to functional dyspepsia. \n</p>\n<p>\n  This is also the second successful expansion of the FDA's indication for IB-Stim after previously getting it approved for abdominal pain associated with irritable bowel syndrome, NeurAxis said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 20, 2025 10:20 ET (14:20 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NRXS","symbol_name":"Neuraxis, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2536645735","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2536645735","pubTimestamp":1747750800,"columns":[{"name":"Product Release","id":31,"label_key":"productRelease"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of NeurAxis more than doubled after regulators cleared its IB-Stim treatment for pediatric functional abdominal pain related to functional dyspepsia.The stock briefly touched a record high of $6.20 before settling back around $4.97 in early trading. Shares closed the market at $5.27 this time a year ago.The medical technology company said before the opening bell that the U.S. Food and Drug Administration's 510 clearance for IB-Stim in patients aged 8 to 21 marks the first time that the FDA has approved a treatment related to functional dyspepsia.This is also the second successful expansion of the FDA's indication for IB-Stim after previously getting it approved for abdominal pain associated with irritable bowel syndrome, NeurAxis said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NRXS":"Neuraxis, Inc.","BK4082":"医疗保健设备"},"translate_title":"FDA批准IB-Stim后NeurAxis股价翻倍","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NRXS":0.9},"content_text":"By Dean Seal \n\n\n \n\n\n  Shares of NeurAxis more than doubled after regulators cleared its IB-Stim treatment for pediatric functional abdominal pain related to functional dyspepsia. \n\n\n  The stock briefly touched a record high of $6.20 before settling back around $4.97 in early trading. Shares closed the market at $5.27 this time a year ago. \n\n\n  The medical technology company said before the opening bell that the U.S. Food and Drug Administration's 510(k) clearance for IB-Stim in patients aged 8 to 21 marks the first time that the FDA has approved a treatment related to functional dyspepsia. \n\n\n  This is also the second successful expansion of the FDA's indication for IB-Stim after previously getting it approved for abdominal pain associated with irritable bowel syndrome, NeurAxis said. \n\n\n \n\n\n  Write to Dean Seal at dean.seal@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 20, 2025 10:20 ET (14:20 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}